Clinical Trial Update: Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating afatinib as monotherapy in ERBB-deregulated metastatic urothelial tract carcinoma after platinum failure has completed with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Cancer
• Urothelial Carcinoma
• Urothelial Tract Carcinoma

Drugs mentioned

• Afatinib (afatinib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Urologic Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2020-10-12